https://scholars.lib.ntu.edu.tw/handle/123456789/416700
Title: | Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling | Authors: | Chen, W.-J. CHAO-CHI HO Chang, Y.-L. Chen, H.-Y. Lin, C.-A. THAI-YEN LING SUNG-LIANG YU Yuan, S.-S. Louisa Chen, Y.-J. Lin, C.-Y. SZU-HUA PAN Elizabeth Chou, H.-Y. Chang, G.-C. WEI-CHENG CHU Lee, Y.-M. Lee, J.-Y. Lee, P.-J. Li, K.-C. Chen, H.-W. PAN-CHYR YANG |
Issue Date: | 2014 | Publisher: | NATURE PUBLISHING GROUP | Journal Volume: | 5 | Journal Issue: | 1 | Source: | Nature Communications | Abstract: | Cancer stem cells (CSCs) are a promising target for treating cancer, yet how CSC plasticity is maintained in vivo is unclear and is difficult to study in vitro. Here we establish a sustainable primary culture of Oct3/4(+)/Nanog(+) lung CSCs fed with CD90(+) cancer-associated fibroblasts (CAFs) to further advance our knowledge of preserving stem cells in the tumour microenvironment. Using transcriptomics we identify the paracrine network by which CAFs enrich CSCs through de-differentiation and reacquisition of stem cell-like properties. Specifically, we find that IGF1R signalling activation in cancer cells in the presence of CAFs expressing IGF-II can induce Nanog expression and promote stemness. Moreover, this paracrine signalling predicts overall and relapse-free survival in stage I non-small cell lung cancer (NSCLC) patients. IGF-II/IGF1R signalling blockade inhibits Nanog expression and attenuates cancer stem cell features. Our data demonstrate that CAFs constitute a supporting niche for cancer stemness, and targeting this paracrine signalling may present a new therapeutic strategy for NSCLC. © 2014 Macmillan Publishers Limited. All rights reserved. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84897058262&partnerID=MN8TOARS https://scholars.lib.ntu.edu.tw/handle/123456789/416700 |
ISSN: | 2041-1723 | DOI: | 10.1038/ncomms4472 60947643 |
Appears in Collections: | 基因體暨蛋白體醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.